Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Tax Provisions: 2019-2024

Historic Tax Provisions for Denali Therapeutics (DNLI) over the last 6 years, with Dec 2024 value amounting to $68,000.

  • Denali Therapeutics' Tax Provisions rose 600.00% to $30,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $272,000, marking a year-over-year decrease of 8.72%. This contributed to the annual value of $68,000 for FY2024, which is 126.67% up from last year.
  • According to the latest figures from FY2024, Denali Therapeutics' Tax Provisions is $68,000, which was up 126.67% from $30,000 recorded in FY2023.
  • In the past 5 years, Denali Therapeutics' Tax Provisions registered a high of $823,000 during FY2020, and its lowest value of -$575,000 during FY2021.
  • Its 3-year average for Tax Provisions is $39,667, with a median of $30,000 in 2023.
  • Its Tax Provisions has fluctuated over the past 5 years, first surged by 334.47% in 2020, then crashed by 169.87% in 2021.
  • Yearly analysis of 5 years shows Denali Therapeutics' Tax Provisions stood at $823,000 in 2020, then slumped by 169.87% to -$575,000 in 2021, then soared by 103.65% to $21,000 in 2022, then skyrocketed by 42.86% to $30,000 in 2023, then spiked by 126.67% to $68,000 in 2024.